10—Milligrams of Paxil prescribed to Reynaldo Lacuzong of San Jose, California, who had no prior history of suicide or suicidal inclinations. After just three days on Paxil, he drowned himself and his two small children in a bathtub.

12%—Rise in suicide for those 15 to 19 years old who took Paxil, from 7.3 per 100,000 in 2003 to 8.2 per 100,000 in 2004; this came after GlaxoSmithKline put a “black-box” warning on Paxel’s label.

14—Times GSK was cited by the Food and Drug Administration for “deceptive and misleading” advertising, between 1997 and 2001.

15—Months that Hannah Mobley of Dunbar, West Virginia lived before succumbing to a heart defect in 2003. Her mother, who had taken Paxil during her pregnancy, later filed suit against GSK. Hannah’s twin sister survived but has a heart defect, as well.

Study 329—Series of clinical trials completed by GSK in 1998. It showed that Paxil was ineffective at treating depression and actually increased the risk of suicide in patients younger than 18. Rather than reveal these Paxil side effects, GSK hired ghostwriters to pressure scientists involved in Study 329. As a result, the Journal of the American Academy of Child and Adolescent Psychiatry soon published an article about the study, falsely claiming that Paxil was helpful in treating depressed adolescents.

5,000—Approximate number of U.S. citizens who have sued GSK over Paxil. Most feel they were insufficiently warned about the drug’s side effects.

$14 million—Paid by GSK in March 2007 to settle a lawsuit over claims that it improperly sought to prevent Paxil’s generic competitors from going on the market.

37 million—Prescriptions written for Paxil in 2002.

$63.8 million—Paid by GSK in 2006 to resolve a Paxil class action suit over claims it promoted the drug for use by children.